Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 9 of 65 · 3079 articles
New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These...
The study points to a possible noninvasive brain-based biomarker that correlates with intestinal fibrosis severity in Crohn’s disease, a complication that’s hard to detect and treat. This could eventually help identify...
MRE is a noninvasive imaging test commonly used to evaluate small-bowel Crohn’s disease, especially when disease is beyond the reach of endoscopy or when repeated follow-up imaging is needed. It helps detect...
AMNs are rare but can be malignant and may mimic UC flares or appendicitis, which can delay diagnosis. For people with long-standing UC, awareness may prompt appropriate imaging and surgical referral.
IBD cases are increasing in Sub-Saharan Africa but care and research remain limited and driven by high-income country priorities. Region-specific research and policy changes could improve diagnosis, treatment access, and...
The study identifies a bacterial mechanism (T6SS) that may help AIEC strains compete with normal gut microbes and colonize the intestinal mucosa — a process relevant to Crohn’s disease biology and future...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Infliximab, and Anti-TNF. The original article is from Frontiers in pediatrics.
Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Research and clinical trials. The original article is from Frontiers in cell and developmental biology.
The study suggests pulmonary nodules are more common in people with Crohn’s disease and that age and certain medications (not disease phenotype) may better predict nodule burden — information that could influence how...
This study raises pharmacovigilance signals and mechanistic hypotheses about liraglutide in people with ulcerative colitis — important because GLP-1 drugs are widely used and are being studied for inflammatory effects....
Knowing ustekinumab levels and anti-drug antibody status may help predict which people with Crohn’s disease are more likely to be in clinical remission and guide treatment adjustments.
People with IBD commonly experience mood disorders; identifying shared molecular signals could help explain why and point to biomarkers or targets for research. This study proposes three genes linked to conserved...
Modeled cost savings and fewer hospital visits could affect access to infliximab for people with Crohn’s disease and other autoimmune conditions in Jordan, potentially increasing the number of patients who can be treated...
Preclinical evidence suggests certain dietary flavonoids may protect the gut barrier, reshape the microbiome, and reduce neuroinflammation, which could be relevant to colitis-linked cognitive problems. This points to...
Standardized, automated severity stratification at diagnosis could help guide early treatment planning and comparability across centers. An AI approach that approximates expert consensus may reduce variability in initial...
This study links higher mucosal PD-L1 expression to active IBD and routine disease activity measures, suggesting the PD-1/PD-L1 immune checkpoint may be involved in intestinal inflammation and could be a biomarker or...
A reliable blood biomarker that predicts relapse while a person with UC is in remission could help tailor monitoring intensity and treatment decisions.
The study identifies a bile acid, TUDCA, that reduced colitis severity and improved gut-barrier and antioxidant pathways in mice, pointing to a potential new therapeutic approach for intestinal inflammation. This is...
Microbiological differences in Crohn’s-related abscesses could affect empirical antibiotic choices and highlight the importance of culture-directed therapy, especially in patients on immunosuppression who showed higher...
Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease, Microbiome, and Research and clinical trials. The original article is from Journal of genetics and...
Adherence affects how well advanced IBD treatments work. Knowing which drug forms and patient factors link to missed doses can help patients and clinicians plan support strategies.
Enteric hyperoxaluria increases risk of calcium oxalate kidney stones and kidney injury. Knowing how common EH is in Crohn's disease and after bariatric surgery helps identify who might benefit from screening and...
Recognition of a local IBD leader signals available specialized multidisciplinary care and ongoing clinical trials activity at UCI Health — relevant for patients seeking advanced treatment or trial participation. It also...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Disinformation Security...
This paper maps where and how mitochondria-related IBD research has grown and what themes (like mitophagy, metabolism, and machine learning) are emerging — useful for researchers, funders, and clinicians tracking...
These Day 1 scores aim to identify patients unlikely to respond to IV steroids so treatment can be escalated earlier; that could shorten delays to rescue therapy and potentially improve outcomes for people admitted with...
A simple blood marker (LBP) that reflects bacterial exposure across the gut barrier was linked to disease severity and immune activity at diagnosis and during follow-up—especially in ulcerative colitis—so it might help...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from Journal of clinical gastroenterology.
Distinguishing Crohn’s disease from appendicitis is a common and important diagnostic problem. Objective CT measurements could help reduce subjective interpretation and guide correct diagnosis, but this study shows...
A high-profile IBD specialist joining a large GI group could expand access to expert IBD care, boost local research activity, and help train new gastroenterologists—changes that may affect patients in South Florida and...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of Food Science...
The study helps explain how granulomas—linked to more severe Crohn’s disease—might form by repurposing lymphoid follicle macrophages, pointing to cellular programs and signals that could be relevant for future biomarkers...
This study supports intestinal ultrasound as a noninvasive, accurate way to detect small-bowel Crohn's activity in many pediatric patients, which could reduce reliance on MRI for routine monitoring. It highlights...
This study suggests mirikizumab can maintain endoscopic and symptomatic improvements for up to two years in many patients with Crohn’s disease, and that IV reinduction can recover response in a subset of 1-year...
Faster, more sensitive capsule endoscopy reading could catch more Crohn’s-related ulcers that might otherwise be missed and reduce the time clinicians spend reviewing long video exams. However, AI increased false...
The study is collecting genetic and clinical data to identify genes that may contribute to IBD risk across populations — information that could inform future research, risk prediction, and understanding of disease...
This national pediatric IBD network aims to collect clinical data and biological samples to study causes of early-onset IBD, track outcomes including intestinal healing and growth, and improve treatment strategies — work...
Fatigue is a common, impactful symptom in Crohn's disease with limited targeted treatments. This early-phase trial is testing whether CoQ10 supplements might reduce fatigue and could inform larger placebo-controlled...
People with UC and PSC have limited study data on microbiome-targeted therapies; this trial asks whether short-course oral vancomycin is feasible and safe in this specific group and will look for early signals in...
Adherence to biologic therapy can affect how well treatment controls IBD; understanding whether self-administered subcutaneous vedolizumab has different adherence than IV infusion could influence treatment choices and...
Noninvasive fecal tests can help detect intestinal inflammation without repeated endoscopy and support treat-to-target care. Better biomarkers could mean earlier treatment changes and less invasive monitoring for people...
This review directly addresses whether switching from originator infliximab to a biosimilar affects disease control or safety in children with IBD — a common practical concern for families and clinicians. Its pooled data...
The study documents shifting real-world prescribing for newly diagnosed IBD in Germany, with more biologic use and less mesalazine/thiopurine in recent years — changes that could affect treatment expectations and access.
The analysis suggests that some biologic and small-molecule therapies work differently depending on whether Crohn's disease affects the ileum, colon, or both — information that could help tailor long-term treatment...
Accurate, consistent severity grading at diagnosis shapes initial treatment decisions in Crohn’s disease. AI that can reproduce expert severity assessments from small labeled datasets could help standardize grading and...
The piece explains emerging strategies that aim to act earlier in the disease process (immune-cell modulation, barrier repair, microbiome change) than current anti-TNF drugs, which could matter to patients seeking future...
People with ulcerative colitis may be interested because the review explains how the gut microbiome and its metabolites could influence disease and evaluates whether traditional Chinese medicines might modify those...
This study helps pinpoint which gut cell types and regulatory DNA regions are most likely to mediate genetic risk for Crohn’s disease, which can guide future research toward relevant cells and pathways.
